evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

403 questions · 428 findings · 117 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 135 · 31.5%GRADE not reported 107 · 25%Very low 90 · 21%Low 44 · 10.3%Moderate 45 · 10.5%High 7 · 1.6%

Summary of findings table ‐ Topical capsaicin vs placebo

Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review

Oral gabapentin vs placebo

Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review

Oral glucosamine hydrochloride/chondroitin sulphate vs placebo

Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review

Oral clonazepam (benzodiazepine) vs placebo

Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review

Cyclosporin (systemic; 10 mg/kg/day for 16 weeks) vs Colchicine (systemic; 1 mg daily)

Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review

Thalidomide (systemic; 100 mg or 300 mg daily) vs placebo

Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
    Males only
    Hamuryudan 1998: significant adverse effects including severe sedation, polyneuropathy, loss of libido, and weight gain; a greater number of adverse events was seen for the higher (300 mg) dose; 4 patients withdrew due…
    1 study · 101 participants
    GRADE not reported

Interferon-alpha (systemic) vs Placebo (subcutaneous)

Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
    Alpsoy 2002: high rate of adverse events including alopecia, leukopenia, and diarrhoea; 18 of 23 patients in the treatment arm experienced mild flu-like symptoms.
    1 study · 50 participants
    GRADE not reported

Group A: amino acids vs placebo

Adverse effects: suicidal thoughts (events) · people in the prodromal stage of psychosis

It is very uncertain whether group A: amino acids changes adverse effects: suicidal thoughts Short‐term (events) compared with placebo (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Protein vs standard diet

Gastrointestinal adverse events · patients (> 65 years) following hip fracture; patients with a recent stroke

It is very uncertain whether summary of findings table ‐ Protein changes side effects: at least one adverse gastrointestinal event compared with standard diet (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Energy, protein and micronutrients vs standard diet

Gastrointestinal adverse events · long‐term care patients; inpatients without dehydration with energy intake by tube feeding; patients with pressure ulcers

It is very uncertain whether summary of findings table ‐ Energy, protein and micronutrients changes side effects: at least one adverse gastrointestinal event compared with standard diet (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Protein, arginine, zinc and antioxidants vs standard diet or placebo

Gastrointestinal adverse events · residents of long‐term care (≥ 65 years) with pressure ulcers; inpatients with pressure ulcers

It is very uncertain whether summary of findings table ‐ Protein, arginine, zinc and antioxidants changes side effects: at least one adverse gastrointestinal event compared with standard diet or placebo (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Arginine and micronutrients vs standard diet

Gastrointestinal adverse events · malnourished patients with pressure ulcers

It is very uncertain whether summary of findings table ‐ Arginine and micronutrients changes side effects: at least one adverse gastrointestinal event compared with standard diet (very low certainty).

1 finding from 1 review

Oral miltefosine (50 mg for 28 days) vs 28 days on/off placebo regimen

Adverse effects (number of participants who had the event) · People with American cutaneous and mucocutaneous leishmaniasis

Oral miltefosine (50 mg for 28 days) probably leads to higher adverse effects (number of participants who had the event) compared with placebo (same regimen) (moderate certainty).

1 finding from 1 review